# A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

> **NCT04840290** · PHASE3 · UNKNOWN · sponsor: **Tang-Du Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin

## Key facts

- **NCT ID:** NCT04840290
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840290, "A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04840290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*